Novacyt boosts FY revenue by 35%

Writer, Stock Market Wire
Wednesday, January 24, 2018 - 08:28

Clinical diagnostics group Novacyt said it boosted sales by 35% in 2017, with all parts of the company achieving double-digit sales growth.

The company ended the year with €4.3m (£3.8m) in cash.

"With continued organic sales growth and strong gross margins, we are aiming to move into profitable trading during 2018 to strengthen the basis for future growth," chief executive Graham Mullis said.

At 8:28am: (LON:NCYT) Novacyt S.a. Eur115th Cdi share price was +3p at 69.5p


Related content

Novacyt signs development contract with GenePOC

Novacyt's molecular testing division, Primerdesign, has entered into a clinical assay development contract with GenePOC, a Canada-based company which specialises in the development and manufacture...

Thu, 22/03/2018 - 08:48


Novacyt makes fast-growing companies list

Novacyt said it has been ranked 135 in Deloitte's Technology Fast 500 EMEA index.

The awards rank 500 technology, media and telecommunications companies with the...

Tue, 02/01/2018 - 09:58